Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Formulations of Perindopril/Indapamide/Amlodipine
NCT05940909Phase 1Unknown
- Sponsor
- Pharmtechnology
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perindopril, indapamide and amlodipine in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve from time 0 to 72 hours. Status: unknown.
02
Drugs
perindoprilindapamideamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05940909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940909.